Oncopeptides AB: Clinical Trials

11 trials sponsored by Oncopeptides AB, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 terminated, 1 approved for marketing, 1 completed, 1 recruiting. 5 Phase 2, 4 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Terminated 4, Completed 1
Phase 14Terminated 3, Withdrawn 1
Phase 32Terminated 2

Follow Oncopeptides AB: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)
Multiple Myeloma
RecruitingiOMEDICO AG502026-06-012026-06-26
A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma
OPD5 - Relapse Multiple Myeloma, Multiple Myeloma
Phase 1WithdrawnOncopeptides AB2021-05-272021-11-26
Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
Melflufen, Dexamethasone, Daratumumab - Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma
Phase 3TerminatedOncopeptides AB542020-12-212023-06-08
A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
Melphalan-Flufenamide (Melflufen), Dexamethasone - AL Amyloidosis
Phase 1TerminatedOncopeptides AB62020-08-062022-03-28
A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients
Melphalan, Dexamethasone - RRMM
Phase 2TerminatedOncopeptides AB272020-08-042023-03-09
PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function
Melflufen, Dexamethasone - Renal Impairment, Multiple Myeloma
Phase 2TerminatedOncopeptides AB352018-08-282023-03-10
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib - Multiple Myeloma
Phase 1 / Phase 2TerminatedOncopeptides AB562018-04-122022-12-19
A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide
Melflufen, Pomalidomide, Dexamethasone - Multiple Myeloma
Phase 3TerminatedOncopeptides AB4952017-06-122024-01-30
A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Melphalan flufenamide (Melflufen), Dexamethasone - Multiple Myeloma
Phase 2CompletedOncopeptides AB1572016-12-282022-11-22
Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
Melflufen, Dexamethasone - Relapsed and/or Relapsed-refractory Multiple Myeloma
Phase 1 / Phase 2TerminatedOncopeptides AB752013-07-012020-10-23
Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma
Melphalan Flufenamide, Dexamethasone - Relapsed and/or Refractory Multiple Myeloma
Approved for marketingOncopeptides AB2021-03-18

Conditions studied

Multiple Myeloma (7)  ·  Immunoglobulin Light-chain Amyloidosis (1)  ·  Renal Insufficiency (1)

Interventions

Dexamethasone (9)  ·  melflufen (9)  ·  L-melphalanyl-p-L-fluorophenylalanine ethyl ester (6)  ·  Calcium Dobesilate (2)  ·  daratumumab (2)  ·  dexamethasone acetate (2)  ·  Bortezomib (1)  ·  Melphalan (1)  ·  darlin protein, Dictyostelium (1)  ·  pomalidomide (1)

Countries

Czechia (7)  ·  United States (7)  ·  Spain (5)  ·  France (4)  ·  Greece (4)  ·  Germany (3)  ·  Italy (3)  ·  Norway (3)  ·  Poland (3)  ·  Bulgaria (2)  ·  Denmark (2)  ·  Hungary (2)  ·  Israel (2)  ·  Netherlands (2)  ·  Russia (2)

Top investigators

Giovanni Palladini, MD (1)  ·  Johan Harmenberg, MD (1)  ·  Johan Harmenberg, MD, PhD (1)  ·  Paul G Richardson, MD (1)  ·  Pieter Sonneveld, Prof. (1)  ·  Sergio Giralt, MD (1)

Results publications

PMID 37355418, PMID 32213344, PMID 33296242, PMID 34671975, PMID 35032434, PMID 37646657, PMID 37646660, PMID 38426292, PMID 41437395

NIH funding

2018 (1), 2019 (1)